Looking forward to this event starting this Friday

Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit.

Wonderful work by Wendy Chen and the Alliance team!

Dana-Farber’s Breast Oncology Center

Just out at npj Breast Cancer
The monarchE trial 🦋findings indicate that adjuvant abemaciclib offers:

➡️ significant improvements📈in invasive DFS and distant relapse-free survival for high-risk early #BreastCancer
OncoAlert 🚨

In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC

Press release out from DESTINY-Breast06

Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - businesswire.com/news/home/2024…

Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 22nd-28th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancer Research

So thankful to Karen and Rob Hale providing their support to allow us to support our amazing division of breast surgery investigators. Brigham and Women’s Department of Surgery Dr. E Mittendorf christinaminami Eliza Hersh Lorentzen, MD

Protocol mandated dose reduction of #Abemaciclib does not compromise efficacy of adjuvant Abema in the #MonarchE trial. Reassuring for patients, and following a common theme in oral targeted therapies. OncoAlert #bcsm

nature.com/articles/s4152…

Important to explore new ADCs. Also critical to understand how ADCs currently perform in our pts. At ASCO24, we will present the largest RW cohort to date of pts receiving T-DXd for MBC, including for HER2-0 MBC & after SG. Collaboration Dana-Farber Yale University. meetings.asco.org/abstracts-pres…

Fun evening supporting breast cancer research at the BCRF hot pink in Boston gala - grateful for BCRF support as we work towards a cure Laura Dominici MD Olga Kantor MD, MS, FACS christinaminami Sara Myers Brigham and Women’s Department of Surgery

Insightful case study on the use of GPT-4 at Dana-Farber just published by Renato Umeton, Ph.D. et al. on NEJM AI. Multiple challenges faced during institutional implementation, many important lessons learned. Read the case study here: ai.nejm.org/doi/full/10.10…

Here we are with Dr Sarah Sammons from Dana-Farber’s Breast Oncology Center

simposiocancerdemama.cl

Dana-Farber’s Breast Oncology Center is leading a trial on the use of #ColdCaps in preventing hair loss with novel #BreastCcancer therapies including sacituzumab, eribulin, or trastuzumab deruxtecan. Contact us for info about the study or visit: dana-farber.org/breast-oncolog…… #ScalpCooling ; PI Elahe Salehi DNP

What a tour de force! Fantastic review of LCIS and invasive lobular carcinoma by Tari King MD #GBCC2024 . Dana-Farber’s Breast Oncology Center Brigham and Women’s Department of Surgery

Fantastic review by Tari King MD on post-neoadj residual calcs with MRI resolution. Cant definitively rule out residual disease in suspicious calcs even with MRI resolution so removal of residual calcs necessary. #GBCC2024 #BCSM Dana-Farber’s Breast Oncology Center Brigham and Women's Hospital

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile. bit.ly/3QmlaID

When Vici Robinson’s breast cancer returned at age 81, she found a program designed for patients like her at Dana-Farber. With her cancer stable, Vici is on the move, doing yoga, and volunteering. blog.dana-farber.org/insight/2024/0…

Our new article is out, led by Olga Martínez-Sáez!

Management of early-stage HER2+ breast cancer and attitudes towards HER2DX in Spain

An online questionnaire was conducted by an independent third-party across 70 medical oncologists highly specialized in breast cancer in Spain…

Happy Administrative Professionals Day! Today is a reminder to acknowledge and celebrate the invaluable contributions of individuals who often work tirelessly behind the scenes. Their professionalism, adaptability, and positive attitude make a significant difference! Thank you 🩵

Antibody–drug conjugates are active in patients with HER2+ breast cancer brain metastases: where do we go from here? Read the editorial on the brain mets analysis from DB03 by Sarah Sammons (Dr Sarah Sammons) and Nancy Lin (@nlinmd) from Dana-Farber’s Breast Oncology Center. esmoopen.com/article/S2059-…